BEIJING – Beigene Ltd. out-licensed its anti-PD-1 monoclonal antibody tislelizumab to Novartis AG in a deal worth up to $2.2 billion, including $650 million up front. Novartis gains rights to develop and commercialize tislelizumab in the U.S., Canada, Mexico, the EU, the U.K., Norway, Switzerland, Iceland, Liechtenstein, Russia and Japan. Read More

PERTH, Australia – Australia’s Medical Technologies and Pharmaceuticals Industry Growth Center (MTPConnect) is boosting funding for the translation and commercialization of research in diabetes, cardiovascular disease and regenerative medicine. Read More

As a virtual 39th J.P. Morgan Annual Healthcare Conference begins, typically one of the biggest events of the year, biopharma dealmaking barreled ahead with five new deals Jan. 11 that could eventually hit $1.04 billion in total. Read More

A decade from now, 2020 likely will be considered a year like no other in terms of the massive amounts of capital raised amid a raging pandemic. Financing transactions of all types smashed records and in terms of volume hit 1,580, a total that was 42% higher than last year. Read More

HONG KONG - U.S. and China-based Terns Pharmaceuticals Inc. closed an $87 million series C financing round that will pave the way for the company’s pipeline of candidates to treat nonalcoholic steatohepatitis (NASH). Read More

CAJICA, Colombia – Brazil's Butantan Institute and the government of the state of Sao Paulo released efficacy results on Jan. 7 for Coronavac, developed by China’s Sinovac Biotech Ltd., that suggest the COVID-19 vaccine is more than 78% effective. Read More

HONG KONG – Tapping into synergies it sees between the U.S. and Chinese biotech industries, Suzhou, China-based Ascentage Pharma Group International is aiming to get its most advanced candidate, HQP-1351, to market this year. Read More

Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief, including: 3D Medicines, Abbvie, Aerpio, Aim Immunotech, Akston, Alteogen, Ana, Argenx, Baxter Biopharma Solutions, Biohaven, Biontech, Bold, Cheplapharm Arzneimittel, Cohbar, Cristal, Curevac, Emergex Vaccines, Fujifilm, Geovax Labs, Humanigen, Iacta, Immunitybio, Intas, Intravacc, Iovaxis, Kleo, Legochem, Merck KGaA, Microsoft, Moderna, Nantkwest, Neurobo, Novavax, Peptidream, Pfizer, Pharmabcine, Pharmaleads, SK Chemicals, Sosei Group, Standigm, Takeda, Targovax, Y-Biologics, Zai Lab. Read More

Biopharmas in Asia-Pacific raising money in public or private financings, including: Ascendis, Gracell, Ligature, Paratek, Revelation Biosciences, Visen, Zai Lab. Read More

Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: AM, Arch Biopartners, Aslan, Atyr, Basilea, Cerecor, Codagenix, Creative Medical Technology, Dalcor, Dr. Reddy’s, Edesa, Immutep, Kintor, Mesoblast, Neurorx, Quantum Leap Healthcare, Relief, Russian Direct Investment Fund, Sanbio, Serum Institute of India, Windtree. Read More

Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Antengene, Apollomics, Arcturus, Ascentage, Astellas, Astrazeneca, Atriva, Everest Medicines, Glaxosmithkline, Glycomimetics, Moderna, Neuren, Russian Direct Investment Fund, Shenzhen Chipscreen Biosciences, Visen Pharmaceuticals Shanghai. Read More